← Browse by Condition
Medical Condition
primary mediastinal b cell lymphoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT02393157 Phase 2
Recruiting
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Enrollment
25 pts
Location
United States
Sponsor
New York Medical College
NCT07283822 Phase 2
Recruiting
Amping up With PemJAK
Enrollment
53 pts
Location
United States
Sponsor
Seda S. Tolu